A61K 40/4273
Glycoprotein 100 [gp100]
Official title: {Glycoprotein 100 [Gp100]}
A61K40/4273 (Glycoprotein 100 [gp100]) appears on 147 US grants and 305 published applications in this corpus.
Search patents in A61K- Granted patents
- 147
- Published applications
- 305
- Assignees
- 165
- Inventors
- 485
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 2 | 0 |
| 2002 | 1 | 6 |
| 2003 | 1 | 2 |
| 2004 | 2 | 8 |
| 2005 | 1 | 4 |
| 2006 | 1 | 7 |
| 2007 | 1 | 4 |
| 2008 | 3 | 10 |
| 2009 | 3 | 7 |
| 2010 | 6 | 7 |
| 2011 | 6 | 6 |
| 2012 | 3 | 7 |
| 2013 | 3 | 3 |
| 2014 | 3 | 8 |
| 2015 | 5 | 7 |
| 2016 | 7 | 12 |
| 2017 | 5 | 13 |
| 2018 | 8 | 18 |
| 2019 | 8 | 23 |
| 2020 | 5 | 22 |
| 2021 | 11 | 27 |
| 2022 | 25 | 42 |
| 2023 | 5 | 18 |
| 2024 | 11 | 24 |
| 2025 | 11 | 8 |
| 2026 | 10 | 12 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of preparing anti-human papillomavirus antigen T cells11 Aug 2026US 12,702,706 B2The United States of America, as represented by the Secretary, Department of Health and Human Seervices
- Engineered T cell receptors and methods of use7 Jul 2026US 12,673,980 B2Board of Regents, The University of Texas System
- MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function9 Jun 2026US 12,648,963 B2Memorial Hospital for Cancer and Allied Diseases
- Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof5 May 2026US 12,617,864 B2Medgene Therapeutics, Inc.
- T cell receptors and methods of use thereof28 Apr 2026US 12,611,450 B2University Health Network
- Il-9r signaling compositions and methods10 Sep 2026US 2026/0263516 A1The Regents of the University of California
- Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy6 Aug 2026US 2026/0226506 A1Genvira Biosciences, Inc.
- Polynucleotides, polypeptides, cells, and compositions comprising synthetic immune receptors with methods of manufacture and treatment18 Jun 2026US 2026/0167693 A1Angeles Therapeutics, Inc.
- Compositions and methods for treating or preventing t cell exhaustion28 May 2026US 2026/0146240 A1
- Low dose lymphodepletion with adoptive cell therapy30 Apr 2026US 2026/0115289 A1Obsidian Therapeutics, Inc.
Most cited
By later US patents
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy98US 8,287,857 B2The United States of America as represented by the Secretary of the Deparment of Health and Human Services · 2012
- Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma79US 6,500,919 B1Introgene B.V. · 2002
- Melanoma antigenic peptides43US 6,306,640 B1Genzyme Corporation · 2001
- Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response33US 7,361,360 B2Lipid Sciences, Inc. · 2008